Christopher U. Missling
Net Worth

Last updated:

What is Christopher U. Missling net worth?

The estimated net worth of Dr. Christopher U. Missling is at least $21,357,453 as of 28 Mar 2024. He owns shares worth $12,127,037 as insider, has earned $2,514,416 from insider trading and has received compensation worth at least $6,716,000 in Anavex Life Sciences Corp..

What is the salary of Christopher U. Missling?

Dr. Christopher U. Missling salary is $671,600 per year as Chairman, Pres, Chief Executive Officer & Sec. in Anavex Life Sciences Corp..

How old is Christopher U. Missling?

Dr. Christopher U. Missling is 59 years old, born in 1966.

What stocks does Christopher U. Missling currently own?

As insider, Dr. Christopher U. Missling owns shares in one company:

Company Title Shares Price per share Total value
Anavex Life Sciences Corp. (AVXL) Chairman, Pres, Chief Executive Officer & Sec. 1,250,210 $9.7 $12,127,037

What does Anavex Life Sciences Corp. do?

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

AVXL logo
AVXL
Anavex Life Sciences Corp.
$9.7

Christopher U. Missling insider trading

Anavex Life Sciences Corp.

Dr. Christopher U. Missling has made 3 insider trades between 2015-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 268,000 units of AVXL stock on 28 Jun 2023. As of 28 Mar 2024 he still owns at least 1,250,210 units of AVXL stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 73,380 $1.32 $96,862
Option
Stock Option (Right to Buy) 73,380 $1.32 $96,862
Sale
Common Stock 73,380 $5.11 $374,972
Option
Common Stock 232,000 $1.6 $371,200
Option
Stock Option (Right to Buy) 232,000 $1.6 $371,200
Sale
Common Stock 268,000 $7.98 $2,139,444
Option
Stock Option (Right to Buy) 268,000 $1.6 $428,800
Option
Common Stock 268,000 $1.6 $428,800
Option
Common Stock 51,620 N/A N/A
Option
Stock Option (Right to Buy) 51,620 N/A N/A
Sale
Common Stock 51,620 N/A N/A
Purchase
Common Stock 1,360 $2.92 $3,971
Purchase
Common Stock 1,450 $2.73 $3,959
Purchase
Common Stock 1,500 $2.63 $3,945
Purchase
Common Stock 1,650 $2.41 $3,977
Purchase
Common Stock 375 $4.39 $1,646
Purchase
Common Stock 375 $4.92 $1,845
Purchase
Common Stock 375 $4.49 $1,684
Purchase
Common Stock 375 $4.27 $1,601
Purchase
Common Stock 750 $4.22 $3,165
Purchase
Common Stock 375 $4.3 $1,613
Purchase
Common Stock 375 $4.2 $1,575
Purchase
Common Stock 375 $4.21 $1,579
Purchase
Common Stock 375 $3.88 $1,455
Purchase
Common Stock 375 $4.23 $1,586
Purchase
Common Stock 375 $4.4 $1,650
Purchase
Common Stock 375 $4.58 $1,718
Purchase
Common Stock 375 $4.81 $1,804
Purchase
Common Stock 375 $4.76 $1,785
Purchase
Common Stock 375 $4.9 $1,838
Purchase
Common Stock 375 $4.48 $1,680
Purchase
Common Stock 375 $4.44 $1,665
Purchase
Common Stock 375 $4.54 $1,703
Purchase
Common Stock 375 $4.07 $1,526
Purchase
Common Stock 375 $3.81 $1,429
Purchase
Common Stock 375 $3.7 $1,388
Purchase
Common Stock 750 $3.55 $2,663
Purchase
Common stock 1,000 $0.52 $518
Purchase
Common stock 1,000 $0.53 $530
Purchase
Common stock 1,000 $0.51 $510
Purchase
Common stock 1,000 $0.51 $510
Purchase
Common stock 1,000 $0.46 $455
Purchase
Common stock 1,000 $0.46 $455
Purchase
Common stock 1,000 $0.47 $468
Purchase
Common stock 1,000 $0.42 $415
Purchase
Common stock 1,000 $0.44 $442
Purchase
Common stock 1,000 $0.43 $428
Purchase
Common stock 1,000 $0.36 $355
Purchase
Common stock 1,000 $0.35 $352
Purchase
Common stock 1,000 $0.37 $369

Anavex Life Sciences Corp. key executives

Anavex Life Sciences Corp. executives and other stock owners filed with the SEC:

  • Dr. Christopher U. Missling (59) Chairman, Pres, Chief Executive Officer & Sec.
  • Ms. Sandra Boenisch CPA, CPA, CGA (44) Principal Financial Officer & Treasurer